Objectives
The severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection originated from China in December 2019 and rapidly spread worldwide. SARS-CoV-2 posed a major challenge for global public health. It is well known that SARS-CoV-2 infection is followed by an immune response and formation of antibodies. Thus, determination of infection seroprevalence can provide important information on SARS-CoV-2 and contribute to proper organization of public health measures. Our study aimed to investigate the possibility of rapid tests application for determination of seroprevalence of SARS-CoV-2 infection.
Results
70 serum samples with determined IgG against nucleocapsid protein of SARS-CoV-2 by enzyme linked immunoassay (ELISA) method were tested by application of rapid immunochromatographic test for the qualitative detection of IgG antibodies to SARS-CoV-2. It has been revealed that by both methods: a) 21 (77.8%) samples are negatives; b) 23 (67.7%) samples are positive; and c) 3 (33.3%) equivocal by ELISA method samples are positive by rapid test, although 6 (66.7%) equivocal by ELISA method samples are negative by rapid test. By consideration of these data we assumed that rapid test for qualitative detection of IgG antibodies to SARS-CoV-2 can be used as screening method for determination of seroprevalence of SARS-CoV-2 infection.